Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
SP600125
Cat. No.:
OB0225LY-0461
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
SP600125 is a small molecule compound that specifically inhibits c-Jun N-terminal kinase (JNK) and plays an important role in the regulation of stress response and cell growth.
Synonym:
1PMV; JNK Inhibitor II; Nsc75890; Pyrazolanthrone; 129-56-6; 1,9-Pyrazoloanthrone; 129-56-6; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one
CAS No.:
129-56-6
Compound CID:
8515
Formula:
C14H8N2O
Formula Weight:
220.23
Specification
Relative Density:
1.463 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
SP600125 can be used to study the function of the JNK signaling pathway or play an important role in the study of neurodegenerative diseases and inflammation.
Library Information
Targets:
MAP kinases; Serine/Threonine & receptor tyrosine kinases
Receptors:
Aurora kinase; JNK1; JNK2; JNK3; TrkA
Pathways:
Apoptosis; Autophagy; Chromatin/Epigenetic; Tyrosine kinase/adaptors; Cell cycle/Checkpoint; MAPK
Plate Number:
AOCL-6
Plate Location:
h8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
50 mg/mL; 227.04 mM
Ethanol Max Solubility:
1.1 mg/mL; 5 mM
Special Max Solubility:
M1.25 mg/mL
